The crisis in antibiotic resistance has resulted in an increasing fear of the emergence of untreatable organisms. Resistance to the glycopeptide antibiotic vancomycin in the enterococci, and the spread of these pathogens throughout the environment, has shown that this scenario is a matter of fact rather than fiction. Enterococci are frequent causes of nosocomial infections and are intrinsically resistant to many antibiotics, being susceptible only to synergistic penicillin͞aminoglycoside therapy or to the glycopeptide antibiotic vancomycin (1). The recent emergence of resistance to vancomycin in these organisms (2, 3) has been greeted with grave alarm, not only because of the immediate problem of how to treat an infection when no other good drugs are available, but also because vancomycin-resistant enterococci (VRE) may serve as a reservoir for Van R genes, which will no doubt eventually make their way into more virulent organisms such as those of the genus Staphylococcus. Highlevel resistance to vancomycin in VRE (minimal inhibitory concentration Ͼ 1,000 g͞ml) is conferred by five genes located on a transposable element (4). These genes include vanR and vanS, which encode a two-component regulatory system that directs the transcription of three structural genes: The origin of the Van R genes has been the subject of some speculation. Related to this question is the increasing debate concerning the prudence of the continued agricultural use of glycopeptide antibiotics such as avoparcin (8-12) in view of the capacity for selection of VRE in the environment (13-15). That environmental VRE isolates have not been observed yet in North America where glycopeptides are not used in agriculture (16), unlike the situation in Europe, adds another dimension to the debate.
Enterococci are frequent causes of nosocomial infections and are intrinsically resistant to many antibiotics, being susceptible only to synergistic penicillin͞aminoglycoside therapy or to the glycopeptide antibiotic vancomycin (1) . The recent emergence of resistance to vancomycin in these organisms (2, 3) has been greeted with grave alarm, not only because of the immediate problem of how to treat an infection when no other good drugs are available, but also because vancomycin-resistant enterococci (VRE) may serve as a reservoir for Van R genes, which will no doubt eventually make their way into more virulent organisms such as those of the genus Staphylococcus. Highlevel resistance to vancomycin in VRE (minimal inhibitory concentration Ͼ 1,000 g͞ml) is conferred by five genes located on a transposable element (4) . These genes include vanR and vanS, which encode a two-component regulatory system that directs the transcription of three structural genes: vanA, vanH, and vanX. VanH is a D-specific ␣-ketoacid dehydrogenase that makes D-lactate (D-Lac) (5) , VanA is a D-Ala-D-Ala ligase (Ddl) that catalyzes the synthesis of D-Ala-D-Lac (5) , and VanX is a dipeptidase that clears cytoplasmic D-Ala-D-Ala synthesized by the endogenous Ddl (6, 7). Vancomycin acts by binding to the terminal D-Ala-D-Ala moiety of the bacterial peptidoglycan thus interfering with normal cell wall growth. As a consequence of the incorporation of D-Ala-D-Lac by VRE into the peptidoglycan layer in place of D-Ala-D-Ala, the affinity of vancomycin for the peptidoglycan diminishes over 1,000-fold, resulting in clinical antibiotic resistance (5) .
The origin of the Van R genes has been the subject of some speculation. Related to this question is the increasing debate concerning the prudence of the continued agricultural use of glycopeptide antibiotics such as avoparcin (8) (9) (10) (11) (12) in view of the capacity for selection of VRE in the environment (13) (14) (15) . That environmental VRE isolates have not been observed yet in North America where glycopeptides are not used in agriculture (16) , unlike the situation in Europe, adds another dimension to the debate.
The amino acid sequence of the vancomycin-resistance enzyme VanA (17) and the related VanB (18) shows between 20% and 35% sequence homology to other Ddls, including the D-Ala-D-Lac ligases from organisms that are intrinsically resistant to vancomycin such as Leuconostoc spp. and Lactobacillus spp. (19) . As part of an ongoing study of the biosynthesis of glycopeptide antibiotics, we have cloned the complete ddl gene from the glycopeptide-producing organism Streptomyces toyocaensis NRRL 15009, which produces the aglycopeptide A47934, and a partial ddl gene from Amycolatopsis orientalis, which produces vancomycin (Fig. 1) . These genes encode proteins that show a high degree of homology to the VanA and VanB ligases and suggest that clinical vancomycin resistance may have originated in glycopeptide-producing organisms.
MATERIALS AND METHODS
Cloning of ddl Genes. Cloning of ligase genes was achieved by PCR amplification using degenerate deoxyoligonucleotide primers designed to amplify an internal ddl fragment of approximately 650 bp (20) . The primers were adjusted to account for the G͞C preference of actinomycetes: 5Ј-GGIG-AGGACGGIT(A)C(G)IC(A)TICAGGG-3Ј, 5Ј-GTGAAIC-CG(C)GGIAT(G)IGTGTT-3Ј. Each polymerase reaction contained genomic DNA as template (500 ng), Taq polymerase, 0.4 mM dNTPs, 1 M primers, and 5.0% dimethyl sulfoxide. The putative 650-bp ddl fragments amplified from S. toyocaensis NRRL 15009 and A. orientalis C329.2 genomic DNA were separately cloned into pGEM-T (Promega) and sequenced in both directions by cycle sequencing methods on an Applied Biosystems automated DNA sequencer. For the A. orientalis internal 650-bp ddl fragment, further cloning and
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sequence analysis of the entire gene was not pursued. To isolate a clone encompassing the complete S. toyocaensis ddl gene as well as upstream and downstream flanking DNA, the 650-bp PCR fragment was randomly labeled with 32 P and served as probe for Southern hybridization of genomic DNA isolated from S. toyocaensis, which was digested to completion using several restriction enzymes in separate experiments. Hybridizing fragments of DNA from digestion with SacI and BamHI were cloned into pBluescript II KSϩ (Stratagene) and pGEM-7Zf (Promega), respectively, and confirmed to contain the ddl gene by colony hybridization. A 3.6-kb BamHI fragment was completely sequenced using a series of overlapping nested deletions created by ExoIII͞S1 nuclease treatment. However, because of an internal BamHI site in the ddlM gene, sequence analysis from the overlapping 3-kb SacI fragment was required to complete the gene sequence. D-Ala-D-X Activity Assays. The 3-kb SacI fragment was subcloned into plasmid pFD666 (21) to give pFD666-Stoyddl, which was used to transform Streptomyces lividans 1326 protoplasts. Cultures (100 ml) of S. lividans 1326 bearing plasmid pFD666 (negative control) or pFD666-Stoyddl were grown for 48 hr in streptomycete antibiotic activity medium (per liter: soytone 15 g, D-glucose 15 g, NaCl 5 g, yeast extract 1 g, CaCO 3 1 g, glycerol 2.5 ml) supplemented with neomycin (1 g͞ml), Mixtures were incubated overnight at ambient temperature, applied to a cellulose TLC plate, and developed as previously described (5).
RESULTS AND DISCUSSION
Cloning of ddl Genes from Glycopeptide Producers. We used a PCR strategy based on the use of degenerate DNA primers that encode regions of homology between all Ddls, an approach that has proven successful for the cloning of other Ddls (e.g., ref. 20) . DNA fragments of Ϸ650 bp were amplified from both S. toyocaensis and A. orientalis genomic DNA. Sequencing of these amplified products revealed strong amino acid homology to Ddls. We therefore cloned the entire gene from S. toyocaensis by standard methods. Complete sequencing of a 4.2-kb region of the genome revealed two ORFs (Fig.  2) . The first ORF, murX, was 1,330 bases in length. Translation and BLAST (22) Sequence Analysis of ddl Gene Products. The S. toyocaensis ddl gene was found to encode a 341 amino acid protein, DdlM, with a predicted molecular mass of 36.7 kDa (Fig. 2) . Alignment of the DdlM amino acid sequence with other Ddl proteins revealed notable homology (20-35% similarity) to the peptide synthesizing D-Ala-D-Ala ligases DdlA, DdlB, and VanC (Fig. 2a) . The homology was, however, especially significant with the D-Ala-D-Lac ligases VanA and VanB from VRE (Ͼ60% similarity) but was moderate (Ϸ25%) with the depsipeptide-synthesizing ligases from intrinsically vancomycin-resistant Gram-positive bacteria such as Leuconostoc mesenteroides and the Lactobacilli. A 600-bp segment of the ddl gene from the vancomycin producer A. orientalis was also cloned and sequenced (Fig. 3) . The translated amino acid sequence, DdlN, was highly similar to the DdlM (72% similarity) and the VanA and VanB enzymes (60% and 62% respective similarity), thus these four enzymes form a distinct subfamily of Ddls (Fig. 4) .
The crystal structure of the E. coli ligase, DdlB, complexed with ADP and a phosphorylated phosphinate inhibitor (25) , along with recent mutagenesis experiments (26, 27) Phe mutant in DdlB has been shown to be capable of D-Ala-D-Lac synthesis (27) .
The precise positioning of the -loop in the acquired D-Ala-D-Lac ligases VanA and VanB is difficult to ascertain as the primary sequence homology breaks down in this region (Fig. 5a ). However, biochemical evidence for the presence of such a loop in VanA has been established (28) . These amino acid sequence differences in the -loop region highlight the unique nature of VanA and VanB and place these enzymes in a separate class that is distinct from other known Ddls. The fact that DdlM and DdlN share dramatic sequence homology with VanA and VanB in the -loop region clearly demonstrates a close evolutionary relationship between the ligases acquired by enterococci and those found in glycopeptide-producing organisms. The Ddls from producing organisms, like VanA and VanB, share broad sequence homology outside the -loop region, especially in substrate binding regions (Fig. 5 b and c) . Thus the -loop structure is a distinguishing feature common to the Ddls from producing organisms, VanA, and VanB.
DdlM Ddl Activity. The close similarity at the amino acid level between Ddls from glycopeptide-producing organisms and the vancomycin-resistance enzymes of enterococci implied that they also shared similar substrate specificities. Cloning of ddlM into glycopeptide-sensitive S. lividans 1326 permitted assay of ligase activity in cell-free extracts. Like VanA, DdlM is a depsipeptide synthase capable of D-Ala-D-Lac biosynthesis (Fig. 6) as assessed by comigration with authentic VanA derived D-Ala-D-Lac (not shown). However, the presence in S. lividans of the ddlM gene did not confer resistance to A47934 or vancomycin at 0.5 g͞ml. This is probably due to a requirement for a VanX analogue to cleave endogenous S. lividans D-Ala-D-Ala as is the case for enterococci (29) .
Implications of This Study. DdlM and DdlN are highly similar in amino acid sequence and enzymatic specificity to the recently emergent enzymes VanA and VanB, which confer high-level resistance to vancomycin in enterococci. This suggests that the resistance proteins currently found in clinical enterococcal isolates may have originated from glycopeptideproducing organisms. The GϩC contents of ddlM and ddlN are FIG. 4 . Phylogenetic relationship among Ddls. Phylogenetic tree prepared using the Clustal V method (23) , the gap penalty and gap length were set to 10. The point accepted mutations (PAM250) weight table (24) was used to define the similarity between sequences (number of matching residues divided by the sum of the mismatched residues ϩ matching residues ϩ gapped residues) using the MegAlign software by DNAstar (Madison, WI). The horizontal axis is the percentage distance between sequences. high (65% and 58%, respectively) compared with VanA (45%) and VanB (48%). Thus recent horizontal transfer of the ddl genes directly from these drug-producing organisms is not evidenced. Nonetheless, the very high amino acid sequence homology suggests possible transfer from a related producer or perhaps via one or more bacterial intermediaries. That antibiotic-producing organisms are the source of resistance genes is not a new concept (30) . More troubling, however, is recent evidence that has shown that some antibiotic preparations are, in fact, contaminated by DNA from producing organisms, including antibiotic-resistance genes (31) . These results signal again that the wide spread use of members of groups of antibiotics with clinical importance should be closely monitored.
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